The Real-World Economic and Clinical Management of Adult Patients with Skin and Soft Tissue Infections (SSTIs) with Oritavancin: Data from Two Multicenter Observational Cohort Studies

BACKGROUND: Oritavancin is a FDA-approved single-dose IV therapy for the treatment of acute bacterial skin and skin structure infections caused (or suspected to be caused) by certain Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). Published data describing the...

Descripción completa

Detalles Bibliográficos
Autores principales: Estrada, Sandy, Lodise, Thomas P., Tillotson, Glenn S., Delaportas, Dino
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7334314/
https://www.ncbi.nlm.nih.gov/pubmed/32588389
http://dx.doi.org/10.1007/s40801-020-00199-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7334314/
https://www.ncbi.nlm.nih.gov/pubmed/32588389
http://dx.doi.org/10.1007/s40801-020-00199-3

Ejemplares similares